SOSV is a global venture capital firm founded in 1995 and headquartered in Princeton, New Jersey. Specializing in seed-to-growth stage investments, SOSV operates multiple accelerator programs worldwide, including HAX for hardware, IndieBio and RebelBio for life sciences, Chinaccelerator and MOX for cross-border internet ventures, Food-X for innovative food solutions, and dlab for blockchain technology. The firm focuses on investments in revolutionary deep technologies aimed at improving human and planetary health, as well as cross-border markets, particularly in Asia. SOSV invests in approximately 150 startups annually, providing support through its resources to accelerate product development and scaling. Over its two-decade history, SOSV has established a strong reputation, consistently ranking among the top venture capital firms globally.

Bpifrance Financement S.A. is a French financial institution that provides a range of financing solutions and support services aimed at fostering the growth of startups, small and medium-sized enterprises (SMEs), and mid-cap companies. It offers various financial products, including medium to long-term loans, export insurance, and leasing options for both tangible and intangible assets. Additionally, Bpifrance supports companies through consulting services, guarantees for bank financing, and training for executives. The organization also engages in direct investments and manages funds aimed at enhancing the financial landscape for businesses at different stages of their development. Established in 1980 and based in Maisons-Alfort, France, Bpifrance was formerly known as OSEO S.A. and rebranded in July 2013. It operates as a subsidiary of Bpifrance SA, reinforcing its commitment to bolstering the French economy through diversified financial solutions.

RA Capital Management, L.P. is a Boston-based venture capital firm focused on growth capital and early-stage investments in the healthcare and life sciences sectors. Established in 2001, the firm specializes in funding companies involved in drug development, medical devices, diagnostics, and biotechnology. It engages in a range of investment stages, from seed funding to later rounds and public offerings, often preferring to co-invest and take board positions. RA Capital targets companies that are innovating in areas such as prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The firm is staffed by professionals with backgrounds in biology, chemistry, and medicine, providing them with a deep understanding of the scientific and regulatory landscape. This expertise allows RA Capital to identify promising technologies and offer strategic guidance, including potential partnerships and insights into public market demands.

Y Combinator is a startup accelerator based in Mountain View, California, founded in 2005. It has pioneered a new funding model for early-stage startups by investing a modest amount of capital, typically around $150,000, in a large number of companies twice a year. Over a three-month program, Y Combinator collaborates closely with these startups to prepare them for investor pitches and enhance their business strategies. Each funding cycle concludes with Demo Day, where startups present to an exclusive audience of investors. Y Combinator focuses on various sectors, including business software, education, healthcare, and financial technology, among others. In addition to initial funding, it offers ongoing support through its extensive alumni network. Since its inception, Y Combinator has funded over 630 startups, contributing significantly to the entrepreneurial ecosystem in Silicon Valley and beyond.

OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, managing approximately $5 billion in assets. The firm specializes in a range of investment strategies, including private equity, venture capital, and public equity, targeting companies across the healthcare spectrum—from startups to large multinational corporations. OrbiMed invests in various sectors within the healthcare industry, including pharmaceuticals, biotechnology, life sciences, medical devices, and health IT. The firm typically invests between $3 million and $150 million, often seeking majority stakes in its portfolio companies. With a global investment approach, OrbiMed operates from offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, West Kowloon, and Luxembourg, focusing on opportunities in North America, Europe, Asia, and Israel. Its investment strategies are underpinned by fundamental analysis, encompassing investments in public equity, fixed income, and alternative markets.

5Y Capital is a private equity and venture capital firm based in Shanghai, China, specializing in seed, startup, early venture, and growth capital investments. Established in 1992, the firm focuses on a diverse range of sectors, including healthcare, technology, fintech, internet services, consumer services, media, and life sciences, among others. It aims to support entrepreneurs in building innovative companies, particularly in China and other emerging markets in Asia/Pacific. Managing approximately USD 5 billion in dual-currency funds, 5Y Capital attracts investments from global sources, including sovereign wealth funds and family offices. The firm typically makes initial investments exceeding USD 500,000 per portfolio company. 5Y Capital operates under the Morningside Group, which is committed to socially responsible investing, particularly in educational opportunities and scientific research.

Sequoia Capital is a prominent venture capital firm founded in 1972 and based in Menlo Park, California. The firm specializes in investing across various stages of startups, including seed, early, and growth stages, and focuses on sectors such as technology, healthcare, financial services, internet, and mobile. Sequoia typically invests between $100,000 and $1 million in seed companies, $1 million to $10 million in early-stage ventures, and $10 million to $100 million in growth investments. The firm operates globally, with significant activities in regions like Israel, China, and India, where it partners with dynamic founders to build successful companies. Sequoia's extensive portfolio includes notable firms and offers valuable insights and resources, benefiting from decades of experience in the venture capital landscape.

Qiming Venture Partners is a prominent venture capital firm established in 2006 and headquartered in Shanghai, with additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early to growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology in China. Since its inception, Qiming has built a reputation as a leading investment firm in the region, managing multiple funds with over $1 billion in assets. The firm aims to support promising entrepreneurs and innovative businesses, contributing to the development of China's dynamic economic landscape.

Novo Holdings, established in 1999, is the holding company of the Novo Group, primarily managing the investment assets of the Novo Nordisk Foundation. Based in Copenhagen, with additional offices in San Francisco and Boston, Novo Holdings focuses on two main investment categories: Life Science Investments, which encompasses funding life science companies at various stages of development, and Financial Investments, which entails managing a diversified portfolio of equity and fixed income securities. As a prominent life science investor, Novo Holdings aims to create long-term value while ensuring that the Foundation can distribute returns for scientific, social, and humanitarian purposes to enhance public health and welfare. The company has also developed initiatives such as Novo Seeds, which supports early-stage applied research in life sciences, and invests in later-stage life science companies through growth equity. Novo Holdings maintains a strategic influence over affiliated companies, aligning their operations with the values and objectives of the Novo Group.

IP Group, founded in 2001 and based in London, specializes in the commercialization of intellectual property derived from research-intensive institutions. The company focuses on identifying and developing valuable intellectual property and forming strategic commercial partnerships to maximize its potential. With a strong background in industry and finance, IP Group offers financial, strategic, and commercial expertise to its clients on an international scale. The firm has established a solid track record of delivering significant results for its portfolio companies, partners, and shareholders, particularly in sectors such as pharmaceuticals and biotechnology. Through its comprehensive approach, IP Group aims to create long-term value while fostering innovation in the marketplace.